CA3220781A1 - Combination therapy for the treatment of enteric neuropathies - Google Patents

Combination therapy for the treatment of enteric neuropathies Download PDF

Info

Publication number
CA3220781A1
CA3220781A1 CA3220781A CA3220781A CA3220781A1 CA 3220781 A1 CA3220781 A1 CA 3220781A1 CA 3220781 A CA3220781 A CA 3220781A CA 3220781 A CA3220781 A CA 3220781A CA 3220781 A1 CA3220781 A1 CA 3220781A1
Authority
CA
Canada
Prior art keywords
combination
scfa
gdnf
use according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220781A
Other languages
English (en)
French (fr)
Inventor
Rodolphe SORET
Nicolas Pilon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus LP
Original Assignee
Transfert Plus LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus LP filed Critical Transfert Plus LP
Publication of CA3220781A1 publication Critical patent/CA3220781A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/124—Acids containing four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3220781A 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies Pending CA3220781A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202549P 2021-06-16 2021-06-16
US63/202,549 2021-06-16
PCT/CA2022/050955 WO2022261765A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Publications (1)

Publication Number Publication Date
CA3220781A1 true CA3220781A1 (en) 2022-12-22

Family

ID=84526051

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220781A Pending CA3220781A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Country Status (8)

Country Link
US (1) US20240366723A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523413A (cg-RX-API-DMAC7.html)
KR (1) KR20240021837A (cg-RX-API-DMAC7.html)
CN (1) CN117615776A (cg-RX-API-DMAC7.html)
AU (1) AU2022294711A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261765A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110440A1 (en) * 2013-01-10 2014-07-17 Biogen Idec Ma Inc. Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Also Published As

Publication number Publication date
EP4355354A4 (en) 2025-04-09
WO2022261765A1 (en) 2022-12-22
JP2024523413A (ja) 2024-06-28
CN117615776A (zh) 2024-02-27
AU2022294711A1 (en) 2023-12-21
US20240366723A1 (en) 2024-11-07
EP4355354A1 (en) 2024-04-24
KR20240021837A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
US8772233B2 (en) Method for promoting regeneration of pancreatic beta-cells by administering neurturin
JP6948250B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
TWI532480B (zh) 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物
JP2025084741A (ja) 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
ES2271968T3 (es) Receptor de factor neurotrofico derivado de linea celular glial.
EP2310039A1 (en) Fgf-9 and its use relating to blood vessels
JP2004532809A (ja) ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
US8796199B2 (en) Uses of Cerberus and derivatives thereof
CN110869386A (zh) 重组神经生长因子的组合物和方法
CN109715191A (zh) 将赘生性细胞转化成非赘生性细胞的药物缔合物及其用途
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
AU749530B2 (en) CNS neuroregenerative compositions and methods of use
US20030215428A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
EP4076499B1 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
US20080089868A1 (en) Retinal stem cell compositions and methods for preparing and using same
Richardson Oligodendrocyte development
KR100409099B1 (ko) 신경 손상 치료 기구
WO2022046771A1 (en) Juvenile protective factors to arrest and reverse aging in the enteric nervous system
Tao Cell surface proteoglycans control astrocyte migration and retinal angiogenesis by regulating basement membrane assembly
WO2015044379A1 (en) A dyrk1a polypeptide for use in preventing or treating metabolic disorders

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526